BioPorto develops and markets antibodies and antibody-based products, including tests to diagnose human disease, both for the benefit of individual patients and to promote efficiency in the health sector. The Company’s developments include a test (NGAL) to diagnose and monitor acute kidney damage.

BioPorto’s strategy is to develop new methods based on its antibody portfolio that can be patented and achieve a wide use in the diagnosis of various diseases.

BioPorto was founded in 2000 and has about 25 employees. The Company’s shares are listed on OMX Nordic Exchange Copenhagen (symbol: BIOPOR).